• Cardiology, Diabetes & Nephrology
    • Cardiology, Diabetes & Nephrology – London
    • Cardiology, Diabetes & Nephrology – Brazil
    • Cardiology, Diabetes & Nephrology – Canada
    • Cardiology, Diabetes & Nephrology – USA
    • Hatter Horizon Series
    • The 18th Malvern Diabetic Foot Conference
    • Previous Events
      • CDNATL 2019 – London
      • CDNATL 2019 – Brazil
      • CDNATL 2018
      • CDNATL 2017
      • CDNATL 2016
      • CDNATL 2015
      • CDNATL 2014
      • CDATL 2013
      • CDATL 2012
      • NATL 2012
      • CDATL 2011
      • CDATL 2010
      • NATL 2010
      • CATL 2009
      • NATL 2009
  • Oncology
    • Cell Therapy at the Limits 2020
    • UCL Frontiers of Oncology 2019
      • Haematology
      • Melanoma
      • Urology
      • Women’s Health
      • Lung Cancer
      • Gastrointestinal Oncology
      • Paediatric Oncology
      • Supporters
    • Previous Events
      • Accelerating Cancer Immunotherapy 2017
        • Introduction
        • Programme
        • Chairs
        • Venue
        • Sponsor Packages
        • Supporters
      • Oncology at the Limits 2017
        • Introduction
        • Chairs
        • Programme
        • Schedule
        • Venue
        • Hotel
        • Information
        • Supporters
        • OATL 2017: Login
      • OATL 2016
      • OATL 2015
      • OATL 2014
      • OATL 2012
      • OATL 2011
      • OATL 2010
  • Multiple Sclerosis
    • Multiple Sclerosis at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2020
    • Previous Events
      • Multiple Sclerosis Nurses at the Limits 2019
        • Introduction
        • Express Interest in MSNATL 2020
        • Programme
        • Chairs
        • Venue
        • Hotel
        • Information
        • Conflict of Interest Forms
        • Supporters
      • MSATL 2018: Introduction
        • MSATL 2018: Programme
        • MSATL 2018: Chairs
        • MSATL 2018: Schedule
        • MSATL 2018: Venue
        • MSATL 2018: Hotel
        • MSATL 2018: Information
        • MSATL 2018: CME Accreditation
        • MSATL 2018: Supporters
        • MSATL 2018: Conflict of Interest Forms
      • MSATL 2017: Introduction
        • MSATL 2017: Chairs
        • MSATL 2017: Schedule
        • MSATL 2017: Programme
        • MSATL 2017: Venue
        • MSATL 2017: Supporters
  • About
    • Academic Founders
    • Independence
    • The Lancet
    • Support & Sponsorship
    • Delegate Invitations
  • Register Interest
  • Archive
    • CDNATL 2019 – London
    • CDNATL 2019 – Brazil
    • Multiple Sclerosis Nurses at the Limits 2019
    • Hatter Horizon Series 2018
    • Multiple Sclerosis at the Limits 2018
    • Cardiology, Diabetes & Nephrology at the Limits 2018
    • Hatter Horizon Series 2017
    • Accelerating Cancer Immunotherapy 2017
    • Oncology at the Limits 2017
  • Supporters

Dr Joseph Bonventre

He has had a long-standing interest in various aspects of cellular injury and repair mechanisms in the kidney with a special emphasis on the role of inflammation, biomarkers and stem cells.

His team has a great deal of experience with various animal models of AKI and chronic kidney disease and their work has been cited more than 43,500 times. He has a citation h-index of 109 and has received two MERIT awards from NIH and serves on NIH Council.

The team have extended their repair and stem cell work to creation of induced pluripotent stem (iPS) cells and the development of an approach to differentiate iPS and embryonic stem cells to cells of the kidney lineage. They published the first demonstration of creation of an iPS cell line from a kidney disease, polycystic kidney disease, which has an abnormality with plausible significance with respect to the etiology of the disease.  iPS cells generated from fibroblasts of humans with autosomal dominant PKD had reduced ciliary levels of polycystin-2 which could be rescued in iPS-derived hepatoblasts by overexpression of polycystin-1.

This work opened up the possibility to conduct “kidney clinical trials in a dish” with patient specific cells that can by evaluated for efficacy of potential therapeutic agents. They also recently reported a rapid and efficient process, derived by techniques guided by principles of kidney development, by which human iPS and ES cells can be differentiated into intermediate mesoderm and subsequently form multisegmented kidney structures containing podocalyxin expressing cell clusters surrounded by a epithelial layer mimicking Bowman’s capsule, flowing into a continuous tubular structure with properties of proximal tubule, followed by loop of Henle and distal convoluted tubule.

« Professor Jim Mann
Professor Roger Stupp »

Hatter Horizon GP Meeting
Tuesday, 3 December 2019
London, UK

Hatter Horizon Series
Monday, 9 December 2019
London, UK

Multiple Sclerosis Nurses at the Limits
Friday, 10 & Saturday, 11 January 2020, London, UK

Multiple Sclerosis at the Limits
Thursday, 23 & Friday, 24 January 2020, London, UK

Frontiers of Oncology: Colorectal Cancer
February 2020, London, UK

Cardiology, Diabetes & Nephrology at the Limits 2020
Monday, 20 - Wednesday, 22 April 2020, London, UK

Cell Therapy at the Limits 2020
Thursday, 21 - Friday, 22 May 2020, London, UK

The 18th Malvern Diabetic Foot Conference
Wednesday, 13 - Friday, 15 May 2020, Malvern, UK

Cardiology, Diabetes & Nephrology at the Limits Brazil
Friday, 17 - Saturday, 18 July 2020, São Paulo, Brazil

Cardiology, Diabetes & Nephrology at the Limits Canada
Monday, 4 - Tuesday, 5 May 2020, Toronto, Canada

  • Contact
  • The Lancet
  • UCL
  • UCT
  • Brigham & Women’s Hospital
  • The University of Campinas
  • Medical Disclaimer
  • Disclosure
  • E-mail Policy
  • Privacy Policy
  • Anti-spam Policy
  • Disclaimer
  • External Links Policy
  • Terms of use
  • Contact
  • The Lancet
  • UCL
  • UCT
  • Brigham & Women’s Hospital
  • The University of Campinas
© 2019 At the Limits Ltd.
This site uses cookies More info